Crushing disappointment is not an uncommon occurrence in the stock market, but it is practically commonplace in the biotech sector. For every Gilead Sciences (Nasdaq: GILD) or Celgene (Nasdaq: CELG), there are many companies whose compounds fail and whose stocks wither away to mere penny prices.

That said, biotech may also be one of the resilient sectors you can find. So long as you still have a few compounds (or a few ideas) and enough cash, you will get a second chance. And if that second chance works out, you will find the market is more than willing to let bygones be bygones.

IN PICTURES: 5 "New" Rules For Safe Investing

Nervous Neurocrine
I decided to write this column when I saw news last week that Neurocrine Biosciences (Nasdaq: NBIX) signed a partnership agreement with Abbot Labs for its promising endometriosis drug (Elagolix). This agreement gives Neurocrine $75 million up front, potentially $500 million more in milestones, and royalties on future sales (probably in the teens) that could be in excess of $350 million if the drug also gets approved for fibroids.

Not so long ago, Neurocrine was all but left for dead when its once-promising sleep aid Indiplon reached a dead end. Just last week, though, the company reached two licensing agreements (the Abbott deal and a separate second deal with Boehringer for certain small agonists relating most prominently to diabetes), and it should have the cash to advance a pipeline that is promising, though at quite an early stage.

Isis And D'Nile
Isis Pharmaceuticals (Nasdaq: ISIS) has certainly known the thrill of (presumed) victory and the agony of defeat. One of the pioneers in antisense technology, Isis has been buffeted by years of clinical failures. Though Isis had once-promising drug candidates for two of the Holy Grails in biotech - inflammatory disease and cancer - they largely all flamed out, and only one drug ever made it to market. Worse yet, that one drug (Vitravene) has been inconsequential in the market.

Still, Isis gamely pressed on and continued to develop its technology. Now the company has a promising cholesterol drug (mipomersen) licensed to Genzyme (Nasdaq: GENZ) and a robust pipeline of drugs, including promising medications for inflammatory disease, cardiovascular disease, diabetes and cancer, as well as numerous partnerships. All in all, by virtue of always having cash (or access to cash) and always trying to push the technology forward, Isis has stayed in the game and could still become the pioneer in antisense technology.

Success Without Success
Let us also consider the case of Vivus (Nasdaq: VVUS) and Nektar (Nasdaq: NKTR). Both of these companies had drugs actually reach the market (though Nektar's position was that of licensor), but both were exceptionally disappointing. Vivus's original erectile dysfunction drug (MUSE) was buried by the likes of Viagra and Cialis, no doubt due in part to a cringe-inducing administration method, while Nektar's involvement in inhaled insulin came a cropper when Pfizer quickly abandoned Exubera. (For more, see The UPs And Downs Of Biotechnology.)

Nevertheless, both companies are now enjoying a second bite at the apple. Vivus has a promising drug for obesity (Qnexa) that should hit the market this year and could reap hundreds of millions in sales. Nektar is not so close to market with its own proprietary drugs (the company still has numerous development deals with other pharmaceutical companies), but its cancer drug NKTR-102 has shown promising data in early trials and could become a major player in time.

Never Say Die
None of the companies discussed in this column have really "made it" yet. What I think is important, though, is to appreciate that a company with sufficient cash and promising compounds in the pipeline can rebound from seemingly devastating setbacks. This is why I am adamant about investors searching out those biotech companies with ample cash on the balance sheet and at least two separate drug development programs (that is, two entirely different compounds, not one compound being developed for two different conditions).

It is inevitable that the majority of biotech drug candidates will fail. What is not so inevitable, though, is that the company itself must fail and that shareholders will be left with nothing. If investors can spend the time to seek out those companies with multiple opportunities for success and diversify their holdings to spread the risk, they too can navigate the tricky minefield of biotech without getting blown up. (For related reading, see Using DCF In Biotech Valuation.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  2. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  3. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  4. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  6. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  7. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  8. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  9. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
  10. Professionals

    Tips for Helping Clients Though Market Corrections

    When the stock market sees a steep drop, clients are bound to get anxious. Here are some tips for talking them off the ledge.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
RELATED FAQS
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. What happens to the shares of stock purchased in a tender offer?

    The shares of stock purchased in a tender offer become the property of the purchaser. From that point forward, the purchaser, ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!